Hepatology and Swiss Hepato-Pancreato-Biliary (HPB) Center

As hepatologists we care for patients with a broad range of diseases affecting the liver, most notably chronic viral hepatitis B and C, non-alcoholic fatty liver disease, liver cirrhosis – the final stage of all chronic liver diseases – and primary liver cancers. Another key role is the evaluation of patients prior to liver transplantation.

The diagnosis and treatment of chronic viral hepatitis has changed dramatically over the last 10 years.
Today, approximately 50 % of patients with chronic hepatitis C can be cured and in the vast majority of patients with chronic hepatitis B a successful suppression of viral replication is possible. We have conducted and participated in numerous treatment trials and we can offer our patients state-of-the-art treatment options which are currently in an early stage of clinical development. Moreover, we are the largest center of the Swiss hepatitis C cohort study, a collaborative research effort funded by the the Swiss National Science Foundation.

All chronic liver diseases can lead to liver cirrhosis and hepatocellular cancer if the disease process can not be stopped. Together with our partners from the department of visceral surgery and transplantation, we can offer state-of-the-art liver transplantation, including living donor liver transplantation. Our five-year survival rate is over 80 % and compares very favourably with other international centers. Hepatological research created the basis for this success and continues to work towards improving outcome.

To better care for our patients with complex liver, bile duct and pancreatic diseases, the department of gastroenterology and hepatology together with the department of visceral and transplantation surgery and the department of oncology have founded the Swiss Center for Hepato-Pancreato-Biliary (HPB) diseases. The establishment of a specialised, high volume center meets the needs of our patients and is our response to compelling evidence that specialised care for patients in a setting that promotes clinical research does improve outcome.

Translational and basic research compliments our clinical work. The role of bile acids in the development and progression of fatty liver disease and biliary fibrosis on the one hand and the immune response of the human body against the hepatitis C virus on the other hand are in the center of our interest. A better understanding of basic mechanism of liver diseases should ultimately lead to an improved patient care in the future.

design and code: naloo